This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2017 Mar;14(3):139.

doi: 10.1038/nrclinonc.2017.5. Epub 2017 Jan 17.

Haematological cancer: Landmark survival achieved in MM

PMID: 28094265
DOI: 10.1038/nrclinonc.2017.5

Comment

Haematological cancer: Landmark survival achieved in MM

David Killock. Nat Rev Clin Oncol. 2017 Mar.

. 2017 Mar;14(3):139.

doi: 10.1038/nrclinonc.2017.5. Epub 2017 Jan 17.

Author

PMID: 28094265
DOI: 10.1038/nrclinonc.2017.5

No abstract available

PubMed Disclaimer

Comment on

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
Durie BGM, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, Thakuri M, Reu F, Reynolds CM, Sexton R, Orlowski RZ, Barlogie B, Dispenzieri A. Durie BGM, et al. Lancet. 2017 Feb 4;389(10068):519-527. doi: 10.1016/S0140-6736(16)31594-X. Epub 2016 Dec 23. Lancet. 2017. PMID: 28017406 Free PMC article. Clinical Trial.

References

1. Lancet. 2017 Feb 4;389(10068):519-527 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations